Title: Interim #Estimates of 2016–17 Seasonal #Influenza #Vaccine #Effectiveness — #USA, Feb. ‘17.
Subject: Human Influenza Viruses, seasonal vaccination, effectiveness estimation.
Source: US Centers for Disease Control and Prevention (CDC), MMWR Morbidity and Mortality Weekly Report, full page: (LINK). Abstract.
Code: [ ]
Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017
Weekly / February 17, 2017 / 66(6);167–171
Format: [ PDF [240 KB] ]
Brendan Flannery, PhD1; Jessie R. Chung, MPH1; Swathi N. Thaker, PhD1; Arnold S. Monto, MD2; Emily T. Martin, PhD2; Edward A. Belongia, MD3; Huong Q. McLean, PhD3; Manjusha Gaglani, MBBS4; Kempapura Murthy, MPH4; Richard K. Zimmerman, MD5; Mary Patricia Nowalk, PhD5; Michael L. Jackson, PhD6; Lisa A. Jackson, MD6; Angie Foust, MS1; Wendy Sessions, MPH1; LaShondra Berman, MS1; Sarah Spencer, PhD1; Alicia M. Fry, MD1
Corresponding author: Brendan Flannery, firstname.lastname@example.org, 404-718-4276.
1Influenza Division, National Center for Immunization and Respiratory Diseases, CDC; 2University of Michigan, Ann Arbor, Michigan; 3Marshfield Clinic Research Foundation, Marshfield, Wisconsin; 4Baylor Scott and White Health, Texas A&M University Health Science Center College of Medicine, Temple, Texas; 5University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 6Group Health Research Institute, Seattle, Washington.
Suggested citation for this article: Flannery B, Chung JR, Thaker SN, et al. Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017. MMWR Morb Mortal Wkly Rep 2017;66:167–171. DOI: http://dx.doi.org/10.15585/mmwr.mm6606a3.
- In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months (1).
- Each influenza season since 2004–05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent influenza-associated, medically attended, acute respiratory illness (ARI).
- This report uses data, as of February 4, 2017, from 3,144 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 28, 2016–February 4, 2017, to estimate an interim adjusted effectiveness of seasonal influenza vaccine for preventing laboratory-confirmed influenza virus infection associated with medically attended ARI.
- During this period, overall vaccine effectiveness (VE) (adjusted for study site, age group, sex, race/ethnicity, self-rated general health, and days from illness onset to enrollment) against influenza A and influenza B virus infection associated with medically attended ARI was 48% (95% confidence interval [CI] = 37%–57%).
- Most influenza infections were caused by A (H3N2) viruses.
- VE was estimated to be 43% (CI = 29%–54%) against illness caused by influenza A (H3N2) virus and 73% (CI = 54%–84%) against influenza B virus.
- These interim VE estimates indicate that influenza vaccination reduced the risk for outpatient medical visits by almost half.
- Because influenza activity remains elevated (2), CDC and the Advisory Committee on Immunization Practices recommend that annual influenza vaccination efforts continue as long as influenza viruses are circulating (1).
- Vaccination with 2016–17 influenza vaccines will reduce the number of infections with most currently circulating influenza viruses. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated as soon as possible.
Keywords: US CDC; USA; Updates; Seasonal Influenza; Vaccines.